Is heparin of value in the management of acute myocardial infarction?

Cardiovascular Drugs and Therapy

Volumn 11, Issue 2, 1997, Pages 111-119

  White, Harvey D ^a  

^a GREEN LANE HOSPITAL   (New Zealand)

Author keywords

Antithrombin therapy; Heparin; Myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT; HEPARIN; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ARTICLE; BLOOD TRANSFUSION; CLINICAL TRIAL; CORONARY ARTERY; COST BENEFIT ANALYSIS; DRUG EFFICACY; DRUG MEGADOSE; FIBRINOLYTIC THERAPY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; STROKE; SUBCUTANEOUS DRUG ADMINISTRATION;

ACUTE DISEASE; ANTICOAGULANTS; DRUG INTERACTIONS; FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; MYOCARDIAL INFARCTION;

EID: 0031002230     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007776613006     Document Type: Article

References (73)

1. Davies MJ, Thoraas AC. Plaque fissuring: The cause of acute myocardial infarction, sudden ischemic death, and crescendo angina. Br Heart J 1985;53:363-73.
2. Mann KG, Tracy PB, Nesheim ME. Assembly and function of prothrombinase complex on synthetic and natural membranes. In: Oates JA, Harwiger J, Ross R, eds. Interaction of Platelets with the Vessel Wall. Washington, DC: American Physiologic Society, 1985:47-57.
3. Fitzgerald DJ, Catella F, Roy L, Fitzgerald GA. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation 1988;77:142-150.
4. Seitz R, Blanke H, Pratorius G, Strauer BE, Egbring R. Increased thrombin activity during thrombolysis. Thromb Haemost 1988;59:541-542.
5. Eisenberg PR, Sherman LA, Jaffe AS. Paradoxic elevation of fibrin peptide A after streptokinase: Evidence for intense thrombosis despite intense fibrinolysis. J Am Coll Cardiol 1987;10:527-529.
6. Owen J, Friedman KD, Grossman BA, Wilkins C, Berke AD, Powers ER. Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity. Blood 1988;76:616-20.
7. Kerins DM, Roy L, Fitzgerald GA, Fitzgerald DJ. Platelet and vascular function during coronary thrombolysis with tissue-type plasminogen activator. Circulation 1989; 80:1718-1725.
8. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2:349-360.
9. Clowes AW, Karnowsky MJ. Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature 1977;265:625-626.
10. Pasini FL, Pasqui AL, Ceceatelli L, Capecchi PL, Orrico A, Perri TD. Heparin inhibition of polymorphonuclear leukocyte activation in vitro: A possible pharmacological approach to granulocyte-mediated vascular damage. Thromb Res 1984;35:527-537.
11. Friedrichs GS, Kilgore KS, Manley PJ, Gralinski MR, Lucchesi BR. Effects of heparin and N-acetyl heparin on ischemia/reperfusion-induced alterations in myocardial function in the rabbit isolated heart. Circ Res 1994;75:701-10.
12. Ejiri M, Fujita M, Miwa K, et al. Effects of heparin treatment on collateral development and regional myocardial function in acute myocardial infarction. Am Heart J 1990;119:248-253.
13. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990;86:385-391.
14. Granger CB, Hirsh J, Califf RM, et al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: Results from the GUSTO-I Trial. Circulation 1996;93:870-878.
15. Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986;315:1109-1114.
16. Théroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1992;327:141-145.
17. Willerson JT, Casscells W. Thrombin inhibitors in unstable angina: Rebound or continuation of angina after argatroban withdrawal? [editorial comment]. J Am Coll Cardiol 1993;21:1048-1051.
18. Simes RJ, Topol EJ, Holmes DR, et al. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion: Importance of early and complete infarct artery reperfusion. Circulation 1995;91:1923-1928.
19. Kroll MH, Schafer AI. Biochemical mechanisms of platelet activation. Blood 1989;74:1181-1195.
20. Ohman EM, Califf RM, Topol EJ, et al. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. Circulation 1990;82:781-791.
21. Kopia GA, Kopaciewicz LJ, Ohlstein EH, Horohonich S, Storer BL, Shebuski RJ. Combination of the thromboxane receptor antagonist, sulotroban (BM 13.177;SK&F 95587), with streptokinase: Demonstration of thrombolytic synergy. J Pharmacol Exp Ther 1989;50:887-895.
22. Cercek B, Lew AS, Hod H, Yano J, Reddy NK, Ganz W. Enhancement of thrombolysis with tissue-type plasminogen activator by pretreatment with heparin. Circulation 1986;74:583-587.
23. Topol EJ, George BS, Kereiakes DJ, et al. A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. Circulation 1989;79:281-286.
24. Verheugt FWA, Marsh RC, Veen G, Galjee MA, de Cock CC, Bronzwaer JGF. High-dose bolus heparin alone as primary reperfusion therapy for acute transmural myocardial infarction: Preliminary results of the ongoing angiographic HEAP Pilot Study (abstrt). Circulation 1994;90:I563.
25. Reilly IAG, Fitzgerald GA. Inhibition of thromboxane formation in vivo and ex vivo: Implications for therapy with platelet inhibitory drugs. Blood 1987;68:180-186.
26. Patrignani P, Filabozzi P, Patrone C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982;69:1366-1372.
27. 2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med 1991;325:1137-1141.
28. Berglund U, Wallentin L. Persistent inhibition of platelet function during long-term treatment with 75mg acetylsalicylic acid daily in men with unstable coronary artery disease. Eur Heart J 1991;12:428-433.
29. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: A randomised comparison of streptokinase vs. tissue plasminogen activator vs. anistreplase and of aspirin plus heparin vs. aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992;339:753-770.
30. Collins R, MacMahon S, Flather M, et al. Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. Br Med J 1996;313:652-659.
31. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990;336:65-71.
32. Turpie AGG, Robinson JG, Doyle DJ, et al. Comparison of high-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. N Engl J Med 1989;320:352-358.
33. Kroon C, de Boer A, Kroon JM, Schoenmaker HC, van der Meer FJM, Cohen AF. Influence of skinfold thickness on heparin absorption. Lancet 1991;337:945-946.
34. Hackett D, Davies G, Chierchia S, Maseri A. Intermittent coronary occlusion in acute myocardial infarction: Value of combined thrombolytic and vasodilator therapy. N Engl J Med 1987;317:1055-1059.
35. Kwon K, Freedman B, Wilcox I, et al. The unstable ST-segment early after thrombolysis for acute infarction and its usefulness as a marker of recurrent coronary occlusion. Am J Cardiol 1991;67:109-115.
36. Hsia J, Hamilton WP, Kleiman N, et al. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1990;323:1433-1437.
37. Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase: Clinical findings through hospital discharge. Circulation 1987;76:142-154.
38. Bleich SD, Nichols TC, Schumacher RR, Cooke DH, Tate DA, Teichman SL. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol 1990;66:1412-147.
39. de Bono DP, Simoons ML, Tijssen J, et al. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: Results of a randomised double blind European Cooperative Study Group trial. Br Heart J 1992;67:122-128.
40. Eisenberg PR, Miletich JP. Induction of marked thrombin activity by pharmacologie concentrations of plasminogen activators in nonanticoagulated whole blood. Thromb Res 1989;55:635-643.
41. Lee CD, Mann KG. Activation/inactivation of human coagulation factor V by plasmin. Blood 1989;73:185-190.
42. Eisenberg PR. Role of heparin in coronary thrombolysis. Chest 1992;101(Suppl):131S-139S.
43. Eisenberg PR, Sherman LA, Rich M, et al. Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysis. J Am Coll Cardiol 1986;7:1255-1262.
44. Galvani M, Abendschein DR, Ferrini D, Ottani F, Rusticali F, Eisenberg PR. Failure of fixed dose intravenous heparin to suppress increases in thrombin activity after coronary thrombolysis with streptokinase. J Am Coll Cardiol 1994;24:1445-1452.
45. Gulba DC, Barthels M, Westhoff-Bleck M, et al. Increased thrombin levels during thrombolytic therapy in acute myocardial infarction: Relevance for the success of therapy. Circulation 1991;83:937-944.
46. Rapold HJ, de Bono D, Arnold AER, et al. Plasma fibrinopeptide A levels in patients with acute myocardial infarction treated with alteplase: Correlation with concomitant heparin, coronary artery patency, and recurrent ischemia. Circulation 1992;85:928-934.
47. Melandri G, Branzi A, Semprini F, Cervi V, Galiè N, Magnani B. Enhanced thrombolytic efficacy and reduction of infarct size by simultaneous infusion of streptokinase and heparin. Br Heart J 1990;64:118-120.
48. The SCATI (Studio sulla Calciparina nell-Angina e nella Trombosi Ventricolare nell'Infarto) Group. Randomised controlled trial of subcutaneous calcium-heparin in acute myocardial infarction. Lancet 1989;2:182-186.
49. Col J, Decoster O, Hanique G, et al. Infusion of heparin conjunct to streptokinase accelerates reperfusion of acute myocardial infarction: Results of a double blind randomized study (OSIRIS) (abstr). Circulation 1992;86:I-259.
50. White HD, Cross DB, Elliott JM, Norris RM, Yee TW. Long-term prognostic importance of patency of the infarct-related coronary artery after thrombolytic therapy for acute myocardial infarction. Circulation 1994;89:61-67.
51. Hochman JS, Choo H. Limitation of myocardial infarct expansion by reperfusion independent of myocardial salvage. Circulation 1987;75:299-306.
52. Sager PT, Perlmutter RA, Rosenfeld LE, McPherson CA, Wackers FJ, Batsford WP. Electrophysiologic effects of thrombolytic therapy in patients with a transmural anterior myocardial infarction complicated by left ventricular aneurysm formation. J Am Coll Cardiol 1988;12:19-24.
53. Prewitt RM, Gu S, Garber PJ, Ducas J. Marked systemic hypotension depresses coronary thrombolysis induced by intracoronary administration of recombinant tissue-type plasminogen activator. J Am Coll Cardiol 1992;20:1626-1633.
54. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996;335:775-782.
55. Antman EM, for the TIMI 9A Investigators. Hirudin in acute myocardial infarction: A safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial. Circulation 1994;90:1624-1630.
56. White H, Aylward P, Frey M, et al. A randomized, doubleblind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO-1). Presented at the American Heart Association Scientific Sessions, Anaheim, California, USA, November 1995.
57. Kontny F, Abildgaard U, Pedersen T, for the FRAMI Study Group. Low molecular weight heparin (fragmin) in acute myocardial infarction (abstrt). J Am Coll Cardiol 1996;27:166A.
58. Heras M, Chesebro JH, Webster MWI, et al. Hirudin, heparin and placebo during deep arterial injury in the pig: The in vivo role of thrombin in platelet-mediated thrombosis. Circulation 1990;82:1476-1484.
59. Heras M, Chesebro JH, Penny WJ, et al. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs: Heparin versus recombinant hirudin, a specific thrombin inhibitor. Circulation 1989;79:657-665.
60. Maraganore JM, Bourdon P, Jablonski I, Ramachandran KL, Kenton JW. Design and characterization of Hirulogs: A novel class of bivalent peptide inhibitors of thrombin. Biochem 1990;29:7095-7101.
61. Collen D, Matsuo O, Stassen JM, Kettner C, Shaw E. In vivo studies of a synthetic inhibitor of thrombin. J Lab Clin Med 1982;99:76-83.
62. Yasuda T, Gold HK, Yaoita H, Leinbach RC, Guerrero JL, Jang I. Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation. J Am Coll Cardiol 1990;16:714-722.
63. Haskel EJ, Prager NA, Sobel BE, Abendschein DR. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion. Circulation 1991;83:1048-1056.
64. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994;90:1631-1637.
65. Neuhaus K, v. Essen R, Tebbe U, et al. Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) Study: A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK). Circulation 1994;90:1638-1642.
66. Antman EM. Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation 1996;94:911-921.
67. Gold HK, Torres FW, Garabedian HD, et al. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris. J Am Coll Cardiol 1993;1:1039-1047.
68. Abendschein DR, Meng YY, Torr-Brown S, Sobel BE. Maintenance of coronary patency after fibrinolysis with tissue factor pathway inhibitor. Circulation 1995;92:944-949.
69. Sitko GR, Ramjit DR, Stabilito II, Lehman D, Lynch JJ, Vlasuk GP. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Circulation 1992;85:805-15.
70. Gruber A, Harker LA, Hanson SR, Kelly AB, Griffin JH. Antithrombotic effects of combining activated protein C and urokinase in non-human primates. Circulation 1991;84:2454.
71. White HD, Yusuf S. Issues regarding the use of heparin following streptokinase therapy. J Thromb Thrombolys 1995;2:5-10.
72. Collins R, Conway M, Alexopoulos D, et al. for the ISIS Pilot Study Investigators. Randomised factorial trial of high-dose intravenous streptokinase, of oral aspirin and of intravenous heparin in acute myocardial infarction. Eur Heart J 1987;8:634-642.
73. O'Connor CM, Meese R, Carney R, et al. for the DUCCS Group. A randomized trial of heparin in conjunction with anistreplase (anisoylated plasminogen streptokinase activator complex) in acute myocardial infarction: The Duke University Clinical Cardiology Study (DUCCS). J Am Coll Cardiol 1994;3:11-18.